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Background: Pneumococcal pneumonia is a disease of the extremes of age. However,
as other traditional risk factors for pneumococcal pneumonia also increase with older
age, it is unclear if older age itself should be an indication for pneumococcal vaccination.
Therefore, we assessed the effect of age on risk for hospitalization for pneumonia and
for pneumococcal pneumonia.
Methods: Using a national hospitalization dataset, all patients ≥16 years hospitalized in
a Swiss hospital with a diagnosis of pneumonia or pneumococcal pneumonia between
2002 and 2015 were included. Multivariable logistic regression analysis was used to test
the association between age (≥50 or ≥65 years) and hospitalization for pneumonia or
pneumococcal pneumonia after adjusting for pneumococcal vaccine indications. Similar
analyses were performed for effect of age on length of stay (LOS) and mortality.
Results: Among a total of 17,619,016 hospitalizations a diagnosis of pneumonia was
present in 421,760 (2.4%) and a diagnosis of pneumococcal pneumonia in 21,610
(0.12%). Age ≥50 years (OR: 3.52 and 2.12, respectively; p for both <0.001) and age
≥65 years (OR: 2.98 and 1.80, respectively; p for both <0.001) as well as most Swiss
pneumococcal vaccine indications were independent predictors of hospitalization with a
pneumonia and pneumococcal pneumonia diagnosis, respectively. Older age with both
age cut-offs were associated with increased LOS (≥50 years: aRR: 1.19 and 1.24,
respectively; age ≥65 years: aRR: 1.60 and 1.20, respectively; p < 0.001 for all) and
mortality (≥50 years: aOR: 4.73 and 2.84, respectively; age ≥65 years: aOR: 2.38 and
2.69, respectively, p < 0.001 for all) in patients with a pneumonia and pneumococcal
pneumonia diagnosis, respectively. The effects of pneumococcal vaccine indications
decreased with older age. The incidences of hospitalizations with a pneumonia diagnosis
and a pneumococcal pneumonia diagnosis increased significantly from the pre-vaccine
era to the PCV7 era and the PCV13 era (p for trend for both analyses <0.001).
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Conclusion: This study confirms the Swiss indications for pneumococcal vaccination
as independent risk factors for pneumonia hospitalizations. Older age itself should
be considered as an additional vaccine indication. Pneumonia and pneumococcal
pneumonia in adults have increased despite pneumococcal vaccination in children.
Keywords: pneumonia, pneumococcus, age, vaccine, indication, incidence, hospitalization
INTRODUCTION
Lower respiratory tract infections and particularly pneumonia
as its most severe manifestation, are the leading infectious
disease related causes of death worldwide (1). Streptococcus
pneumoniae is the most common etiology of community-
acquired pneumonia (CAP) likely responsible for 40–50% of
pneumonias (2–4). The age-related incidence of pneumococcal
disease shows a U-shaped curve with highest risks in young
children and the elderly (5). Older age itself has been shown to
be an independent risk factor for pneumonia (6). It was shown
that non-immunocompromising conditions which predispose to
pneumococcal disease, such as diabetes mellitus, chronic heart
and lung disease, increase with age in elderly adults, and thus play
an increasing role as a pneumonia risk factor (7, 8). Furthermore,
the presence of these non-immunocompromising conditions,
especially if occurring concomitantly, conferred very high risks.
National recommendations for pneumococcal vaccination in
adults differ on whether age alone in the absence of other
known risk factors, should be a vaccine indication and what
the age cut-off should be (9). In Switzerland, age was removed
from the indication list for pneumococcal vaccination for adults
in 2014 when the 13-valent pneumococcal conjugate vaccine
(PCV13) was first recommended and replaced the 23-valent
polysaccharide vaccine for persons with any pneumococcal risk
factor >5 years of age.
Contemporary data on the incidence of pneumococcal
pneumonia in Switzerland are unavailable. However, beside
national data on IPD, all hospitalizations with associated ICD-
codes as provided by the hospitals are recorded in a national
database. In the absence of individually matched microbiology
data, S. pneumoniae can be assumed the leading etiology among
hospitalized patients with an International Classification of
Disease version 10 (ICD-10) code for pneumonia.
Using this national hospitalization database we therefore
attempted to assess the effect of age as an independent risk
factor for hospitalization for pneumonia and for pneumococcal
pneumonia, which is vaccine preventable. We also analyzed the
effect of age on length of stay (LOS) and mortality in these
patients as markers of severity.
METHODS
Datasets
The hospitalization dataset (https://www.bfs.admin.ch/bfs/
de/home/statistiken/gesundheit/erhebungen/ms.html) used
in this analysis was provided by the Swiss Federal Office
for Statistics. It includes medical information about all
hospitalizations in Switzerland since 1998. In this database,
the patient information is fully anonymized. No written
informed consent was given by patients who were unidentifiable
due to the anonymization. The data belong to the Swiss
Federal Office for Statistics (Bundesamt für Statistik,
Neuchâtel, Switzerland) which provides regulated access
to the data for research purpose. The database included
geographical and temporal information [patient’s age, area
of residence, canton of institution, year and month of
hospitalization, LOS and discharge information (including
death)]. Unique anonymized institution numbers were
also available.
The patients’ list of diagnoses included one main diagnosis
and up to 50 additional diagnoses coded using ICD-10 codes.
The datasets used for the demographic data are publicly
available and were provided by the Federal Office for Statistics
(Statistik des jährlichen Bevölkerungsstandes, ESPOP, for 2002–
2010 and Statistik der Bevölkerung und Haushalte, STATPOP,
for 2011–2015).
All patients aged ≥16 years who were hospitalized in a
Swiss hospital with a pneumonia diagnosis (ICD-10 codes: J13
[pneumonia due to S. pneumoniae], J15 [bacterial pneumonia
not elsewhere classified], J18 [pneumonia, organism unspecified]
listed as either primary diagnosis or non-primary diagnosis)
between 2002 and 2015 were included in this analysis.
In addition, separate analyses were performed restricted to
patients with pneumococcal pneumonia (J13). There were no
exclusion criteria.
As pneumonia risk factors, ICD-10 codes were used
which represented as closely as possible the conditions and
comorbidities which are listed as indications for pneumococcal
vaccination according to Swiss recommendations (see
Appendix) (10).
In concordance with previous publications (11), the
time period from 2002 to 2006 was considered the “pre-
vaccine era.” Despite an official recommendation for PCV7 in
children <2 years starting in November 2005, the coverage
with the 1st dose of PCV7 was only 2% between 2005
and 2007 according to the Swiss National Vaccination
Coverage Survey (Durchimpfung bei 2-jährigen Kindern
in der Schweiz, Erhebungsperioden 1999–2003, 2005–
2007, 2008–2010; https://www.bag.admin.ch/dam/bag/de/
dokumente/mt/i-und-b/durchimpfung/tabelle-durchimpfung.
xlsx.download.xlsx/tabelle-durchimpfung-de.xlsx). 2007–2010
was considered the “PCV7 era,” when PCV7 was recommended
for children <2 years; and 2011–2015 was considered the
“PCV13 era” when PCV13 was recommended for children
<5 years.
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Statistical Considerations
Proportions of hospitalization due to pneumonia were calculated
among persons with and without the respective risk factors.
Differences between proportions were tested using χ2 tests.
Univariate and bivariate (controlling for individual vaccine
indications) analyses were performed to assess the effect of
age (≥50 years or ≥65 years) and other risk factors on the
risk of hospitalization for pneumonia and for pneumococcal
pneumonia. Multivariable logistic regression analysis was used
to test the association between pneumonia or pneumococcal
pneumonia and age (≥50 years or ≥65 years) after adjusting
for the presence of risk factors (i.e., individual pneumococcal
vaccine indications). Interaction between age and risk factors was
calculated to assess for effect modification. As sensitivity analyses,
we calculated trends over time separately for pneumonia
and pneumococcal pneumonia listed as any diagnosis and as
primary diagnosis. Results are reported using odds ratios for
hospitalization and in-hospital mortality or relative risks for LOS
with 95% confidence intervals. Persons without the respective
risk factor were considered the reference group. The associations
between continuous variable and the presence of pneumonia or
pneumococcal pneumonia diagnosis or risk factors were tested
using the Wilcoxon rank sum test. Changes over time were
assessed using X2-test for trend in proportions and Poisson
regression. All analyses were done using the R statistical software.
RESULTS
This study period included a total of 17,619,016 hospitalization
cases among which 421,760 cases (2.4%) included a
pneumonia diagnosis and 21,610 (0.12%) a diagnosis of
pneumococcal pneumonia.
Risk of Pneumonia Hospitalization
In univariate analyses, age ≥50 years (vs. <50 years) [odds
ratio (OR): 4.98, 95%CI: 4.93–5.03] and age ≥65 years (vs.
<65 years) (OR: 4.14; 95%CI: 4.11–4.17) were significant risk
factors for hospitalization with a diagnosis of pneumonia vs.
hospitalization without a diagnosis of pneumonia (Table 1A).
All Swiss pneumococcal vaccine indications (based on respective
ICD-10 codes) were significantly associated with an increased
risk for hospitalization with a diagnosis of pneumonia vs.
hospitalization without a diagnosis of pneumonia. Heart failure,
chronic lung disease and immunodeficiency conferred the
highest risks (Table 1A).
In bivariate analyses and in multivariable logistic regression
each vaccine indication and the age categories≥50 years and≥65
years were significant independent risk factors for hospitalization
with pneumonia (Table 1A). In all bivariate analyses with the
outcome pneumonia hospitalization, the interaction term of risk
factor∗age was negatively correlated with the risk of pneumonia
hospitalization (OR < 1) indicating a decreasing effect of each
risk factor with increasing age.
Risk of Pneumococcal Pneumonia
Hospitalization
When restricted to pneumococcal pneumonia, age ≥50 years
(vs. <50 years) (OR: 2.90, 95%CI: 2.80–3.00) and age ≥65
years (vs. <65 years) (OR: 2.42; 95%CI: 2.36–2.49) were
significant risk factors for hospitalization with a diagnosis of
pneumococcal pneumonia vs. hospitalization without a diagnosis
of pneumococcal pneumonia.
All pneumococcal vaccine indications (based on respective
ICD-10 codes) except for asplenia were significantly associated
with an increased risk for hospitalization with a diagnosis of
pneumococcal pneumonia vs. hospitalization without a diagnosis
of pneumococcal pneumonia. Chronic lung disease, HIV and
immunodeficiency conferred the highest risks (Table 1B).
In bivariate analyses and in multivariable logistic regression
each vaccine indication and the age categories ≥50 years
and ≥65 years were significant independent risk factors for
hospitalization with pneumococcal pneumonia (Table 1B). In
all bivariate analyses (except for asplenia) with the outcome
pneumococcal pneumonia hospitalization, the interaction term
of risk factor∗age was negatively correlated with the risk of
pneumococcal pneumonia hospitalization (OR < 1) indicating
a decreasing effect of each risk factor with increasing age.
Incidence of Pneumonia Hospitalizations
Over Time
Figure 1 illustrates an increasing incidence over time of
hospitalization with pneumonia as any diagnosis (Figure 1A)
and as primary diagnosis (Figure 1B) over time, stratified for age
<50 years (p < 0.001 and p= 0.64, respectively), age 50–64 years
(p< 0.001 for both analyses) and for age≥65 years (p< 0.001 for
both analyses). For pneumococcal pneumonia hospitalization,
there was an increasing incidence as any diagnosis (Figure 2A)
or as primary diagnosis (Figure 2B) over time only for age 50–
64 years (p = 0.001 and p = 0.01, respectively) and for age ≥65
years (p < 0.001 for both analyses) whereas no increase for age
<50 years (p = 0.38 and p = 0.17, respectively). The proportion
of pneumococcal pneumonia showed no clear trend over time as
illustrated in Figure 3.
The unadjusted proportions of hospitalizations with a
pneumonia diagnosis and a pneumococcal pneumonia diagnosis
increased significantly from 1.9% in the pre-vaccine era to
2.3% in the PCV7 era and to 3.0% in the PCV13 era, and
from 0.09 to 0.13% and 0.15%, respectively (p for trend
for both analyses <0.001; Table 2; Figure 4). Similarly, the
incidences of hospitalizations with a pneumonia diagnosis and a
pneumococcal pneumonia diagnosis increased significantly from
376/100,000 inhabitants in the pre-vaccine era to 457/100,000
inhabitants in the PCV7 era and 536/100,000 inhabitants in the
PCV13 era and from 18/100,000 to 26/100,000 and 27/100,000,
respectively (p for trend for both analyses <0.001; Table 2).
Impact of Pneumonia and Pneumococcal
Pneumonia Diagnosis on Outcome
In two separate logistic regressions controlling for the presence of
any pneumococcal vaccine indication, age ≥50 years (aOR: 4.73;
95%CI: 4.42–5.05) and age ≥65 years (aOR: 2.38; 95%CI: 2.30–
2.47) were independent risk factors for in-hospital mortality in
patients with a pneumonia diagnosis (Table 3). In two further
separate logistic regressions controlling for the presence of
any pneumococcal vaccine indication, age ≥50 years [adjusted
relative risk (aRR): 1.32; 95%CI: 1.32–1.33] and age ≥65
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TABLE 1A | Hospitalizations with pneumonia in persons with and without risk factors.
Risk factor Proportion of hospitalizations
with pneumonia of all hospitalizations
in
Univariate
analysis
Bivariate (controlling for
age ≥50, interaction)
analysis
Bivariate (controlling for
age ≥65, interaction)
analysis
Multivariable
analysis with age
≥50
Multivariable
analysis with age
≥65
Patients with risk factor Patients
without risk
factor
OR p OR RF OR age
≥50
Inter-
action
OR RF OR age
≥65
Inter-
action
OR p OR p
Age ≥50y 375,591/11,042,751
(3.4%)
46,169/65,76265
(0.7%)
4.98 <0.001 3.52 <0.001
Age ≥65y 308,868/7,151,622
(4.3%)
112,892/10,467,394
(1.1%)
4.14 <0.001 2.98 <0.001
Heart failure 71,159/597,777
(11.9%)
350,601/17,021,239
(2.0%)
6.43 <0.001 10.0* 4.4* 0.5* 7.6* 3.7* 0.5* 3.16 <0.001 2.94 <0.001
Lung disease (COPD,
severe asthma,
bronchiectasis)
82,373/758,999 (10.9%) 339,387/16,860,017
(2.0%)
5.93 <0.001 7.8* 4.5* 0.6* 8.3* 4.1* 0.5* 3.73 <0.001 3.71 <0.001
Liver cirrhosis 5,215/110,922
(4.7%)
416,545/17,508,094
(2.4%)
2.02 <0.001 7.0* 5.0* 0.2* 4.3* 4.2* 0.3* 1.25 <0.001 1.47 <0.001
Asplenia 29/682
(4.3%)
421,731/17,618,334
(2.4%)
1.81 0.002 6.8* 5.0* 0.2* 4.3* 4.1* 0.2* 1.41 0.09 1.53 0.03
Chronic kidney disease
(nephrotic syndrome)
63,150/713,569
(8.8%)
358,610/16,905,447
(2.1%)
4.5 <0.001 7.6* 4.5* 0.4* 5.9* 3.8* 0.4* 1.96 <0.001 1.77 <0.001
Sickle cell disease 213/2,844
(7.5%)
421,547/17,616,172
(2.4%)
3.3 <0.001 11.7* 5.0* 0.2* 7.5* 4.1* 0.2* 7.80 <0.001 6.45 <0.001
Diabetes mellitus,
poorly controlled with
heart or renal
insufficiency
68,308/124,6291
(5.5%)
353,452/16,372,725
(2.2%)
2.6 <0.001 4.3* 4.8* 0.4* 3.6* 4.2* 0.5* 1.39 <0.001 1.39 <0.001
Lymphoma, leukemia,
myeloma
17,134/213,344
(8.0%)
404,626/17,405,672
(2.3%)
3.7 <0.001 5.8* 5.0* 0.5* 5.3* 4.2* 0.5* 2.73 <0.001 2.77 <0.001
CSF leak 246/9,235
(2.7%)
421,514/17,609,781
(2.4%)
1.2 0.10 2.8* 5.0* 0.3* 2.2* 4.1* 0.3* 1.13 0.06 1.21 0.003
Autoimmune disease 12,891/297,036
(4.3%)
408,869/17,321,980
(2.4%)
1.9 <0.001 2.2* 5.0* 0.7* 2.2* 4.2* 0.7* 1.44 <0.001 1.44 <0.001
HIV 1,518/19,428
(7.8%)
420,242/17,599,588
(2.4%)
3.5 <0.001 11.8* 5.1* 0.2* 7.8* 4.2* 0.3* 4.94 <0.001 5.27 <0.001
Immunodeficiency 3,511/26975
(13.0%)
418,249/17,592,041
(2.4%)
6.1 <0.001 12.4* 5.0* 0.4* 10.3* 4.2* 0.4* 3.34 <0.001 3.74 <0.001
Any risk factor (except
for age)
223,445/3,110,140
(7.2%)
198,315/14,508,876
(1.4%)
5.6 <0.001 6.5* 3.6* 0.6* 6.3* 3.6* 0.6*
*p < 0.001.
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TABLE 1B | Hospitalizations with pneumococcal pneumonia in persons with and without risk factors.
Risk factor Proportion of hospitalizations
with pneumonia of all hospitalizations
in
Univariate
analysis
Bivariate (controlling for
age ≥50, interaction)
analysis
Bivariate (controlling for
age ≥65, interaction)
analysis
Multivariable
analysis with age
≥50
Multivariable
analysis with age
≥65
Patients with risk factor Patients
without risk
factor
OR p OR RF OR age
≥50
Inter-
action
OR RF OR age
≥65
Inter-
action
OR p OR p
Age ≥50y 17,928/11,042,751
(0.2%)
3,682/6,576,265
(0.056%)
2.90 <0.001 2.12 <0.001
Age ≥65y 13,466/7,151,622
(0.2%)
8,144/10,467,394
(0.1%)
2.42 <0.001 1.8 <0.001
Heart failure 2,566/597,777 (0.4%) 19,044/17,021,239
(0.1%)
3.85 <0.001 6.6* 2.7* 0.4* 4.8* 2.2* 0.6* 1.9 <0.001 2.94 <0.001
Lung disease (COPD,
severe asthma,
bronchiectasis)
5,196/758,999
(0.7%)
16,414/16,860,017
(0.1%)
7.07 <0.001 8.8* 2.5* 0.6* 9.1* 2.3* 0.6* 5.1 <0.001 5.1 <0.001
Liver cirrhosis 415/110,922
(0.4%)
21,195/17,508,094
(0.1%)
3.10 <0.001 10.4* 2.9* 0.2* 5.7* 2.5* 0.3* 2.0 <0.001 2.2 <0.001
Asplenia 3/682
(0.4%)
21,607/17,618,334
(0.1%)
3.60 0.027 16.5* 2.9* 0.0 7.9* 2.4* 0.0 2.1 0.19 2.2 0.17
Chronic kidney disease
(nephrotic syndrome)
2,524/713,569 (0.4%) 19,086/16,905,447
(0.1%)
3.14 <0.001 6.0* 2.7* 0.4* 4.6* 2.3* 0.5* 1.5 <0.001 1.5 <0.001
Sickle cell disease 6/2,844 (0.2%) 21,604/17,616,172
(0.1%)
1.72 0.184 3.5** 2.9* 0.6 2.6** 2.4* 0.2* 2.5 0.02 2.2 0.058
Diabetes mellitus,
poorly controlled with
heart or renal
insufficiency
3,125/1246291
(0.3%)
18,485/16,372,725
(0.1%)
2.22 <0.001 3.1* 2.8* 0.5* 2.9* 2.4* 0.5* 1.3 <0.001 1.3 <0.001
Lymphoma, leukemia,
myeloma
1,007/213,344
(0.5%)
20,603/17,405,672
(0.1%)
4.00 <0.001 4.5* 2.9* 0.7** 4.8* 2.4* 0.6* 2.9 <0.001 3.0 <0.001
CSF leak 18/9,235
(0.2%)
21,592/17,609,781
(0.1%)
1.59 0.049 4.8* 2.9* 0.2* 3.4* 2.4* 0.1** 1.6 0.049 1.7 0.03
Autoimmune disease 563/297,036
(0.2%)
21,047/17,321,980
(0.1%)
1.56 <0.001 1.9* 2.9* 0.7** 1.8* 2.4* 0.7* 1.2 <0.001 1.2 <0.001
HIV 246/19,428
(1.3%)
21,364/17,599,588
(0.1%)
10.55 <0.001 2.5* 3.0* 2.7* 17.7* 2.5* 0.2* 11.2 <0.001 11.1 <0.001
Immunodeficiency 255/26,975
(0.9%)
21,355/17,592,041
(0.1%)
7.85 <0.001 14.0* 2.9* 0.5* 11.4* 2.4* 0.5* 3.9 <0.001 4.1 <0.001
Any risk factor (except
for age)
11,319/3110140
(0.4%)
10,291/14,508,876
(0.1%)
2.33 <0.001 3.7* 2.4* 0.6* 6.3* 2.0* 0.6*
*p < 0.001; **p < 0.05.
Reference groups: persons without the respective risk factor. For multivariable analysis, all risk factors (heart failure, lung disease, liver cirrhosis, asplenia, chronic kidney disease, sickle cell disease, diabetes, lymphoma, leukemia,
myeloma, CSF leak, autoimmune disease, HIV, immunodeficiency) were included in 2 analyses, i.e., one analysis for adults ≥50 years and one analysis for adults ≥65 years.
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FIGURE 1 | (A) Incidence of pneumonia hospitalization (any diagnosis) over time, stratified for age groups. (B) Incidence of pneumonia hospitalization (primary
diagnosis) over time, stratified for age groups.
FIGURE 2 | (A) Incidence of pneumococcal pneumonia hospitalization (any diagnosis) over time, stratified for age groups. (B) Incidence of pneumococcal pneumonia
hospitalization (primary diagnosis) over time, stratified for age groups.
years (aRR: 1.16, 95%CI: 1.16–1.17) were independent risk
factors for increased LOS in hospitalized patients with a
pneumonia diagnosis.
The interaction terms of any risk factor∗ age were negatively
correlated with mortality and with LOS (OR < 1) indicating a
relatively decreasing effect of any risk factor with increasing age.
Similarly, age ≥50 years and age ≥65 years were independent
risk factors for in-hospital mortality and for LOS in patients with
a pneumococcal pneumonia diagnosis (Table 3). The interaction
terms of any risk factor∗ age were negatively correlated with
mortality and with LOS (OR < 1) indicating a relatively
decreasing effect of each listed risk factor with increasing age.
DISCUSSION
This study highlights several relevant aspects of pneumonia
etiology in Swiss adults. First, the Swiss indications for
pneumococcal vaccine were independent risk factors for
hospitalization with both pneumonia and pneumococcal
pneumonia. Increasing age was also an independent risk
factor for hospitalization with pneumonia and pneumococcal
pneumonia after controlling for other known risk factors. Older
FIGURE 3 | Proportion of pneumococcal pneumonia hospitalizations
over time.
age was also significantly associated with in-hospital mortality
and increased LOS in adults hospitalized with pneumonia and
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TABLE 2 | Hospitalizations with pneumonia and pneumococcal pneumonia over time.
Pre-vaccine era
(2002-2006)
PCV7 era
(2007-2010)
PCV13 era
(2011–2015)
P for trend
Proportions of hospitalizations with pneumonia (among all hospitalizations) 1.9% 2.3% 3.0% <0.001
Incidence of hospitalizations with pneumonia (/100’000/y) 376 457 536 <0.001
Proportions of hospitalizations with pneumococcal pneumonia (among all hospitalizations) 0.09% 0.13% 0.15% <0.001
Incidence of hospitalizations with pneumococcal pneumonia (/100’000/y) 18 26 27 <0.001
The incidence of hospitalizations with pneumonia was calculated per 100,000 inhabitants of Switzerland per year (averaged over the respective era).
pneumococcal pneumonia. The relative effect of individual risk
factors on hospitalization with pneumonia and pneumococcal
pneumonia and on markers of severity of pneumonia, i.e.,
LOS and in-hospital mortality, decreased with older age. And
finally, hospitalizations with pneumonia and with pneumococcal
pneumonia in persons ≥16 years have increased significantly in
Switzerland since 2002.
All indications for pneumococcal vaccination in adults were
significantly associated with hospitalization with pneumonia
except for CSF leak and asplenia which were not significant or
showed non-significant trend. Our data therefore support the
current list of age-independent indications for pneumococcal
vaccination in adults in Switzerland (10). In addition, older age
was also an independent risk factor for hospitalization with
pneumonia and for pneumococcal pneumonia. We used age cut-
offs of 50 years and of 65 years, which are used as the age
cut-offs in the Austrian and US or UK vaccination schedules,
respectively. The magnitude of the age effect was similarly high
for both age cut-offs (OR 3–3.5 for pneumonia hospitalization
and 1.8–2.1 for pneumococcal pneumonia hospitalization) and
in the range of some of the best established age-independent
risk factors supporting the importance of age. These results
are thus in line both with data from other countries with
surveillance systems, and international guidelines to recommend
pneumococcal vaccination for elderly independent from risk
factors. For example, German healthcare claims data for
3.4 million persons during 2009–2012 illustrated that adults
≥60 years without known chronic diseases had similar rates
of all-cause pneumonia as adults aged 50–59 years with 1
pneumococcal vaccine indication or adults aged 18–49 years with
2 pneumococcal vaccine indications (12). Similarly, US data from
2006 to 2010 showed that healthy adults ≥65 years had a 4–
5 times higher risk of all-cause pneumonia or pneumococcal
pneumonia compared to young adults 18–49 years of age (13).
Interestingly, in the US study (13), but not in the German study
(12), there was also a smaller effect of high-risk conditions in
the older age groups confirming the effect modification between
age and risk factors in our study. This observation might be
explained by the phenomenon of immunosenescence which is
also observed in otherwise healthy older persons and therefore
ameliorates the difference in pneumonia risk to age-matched
persons with chronic conditions.
Our study contributes to a small but increasing number
of publications which investigated the effect of pediatric
pneumococcal vaccination programs on the incidence of
pneumonia in non-vaccinated age groups over time. We noted
FIGURE 4 | (A) Proportion of hospitalizations with pneumonia and
pneumococcal pneumonia (among all hospitalizations). (B) Incidence of
hospitalizations with pneumonia and pneumococcal pneumonia.
an increased incidence from the pre-vaccine era to the PCV7
era and to the PCV13 era; increases were most apparent in the
age groups 50–64 years and those ≥65 years, This is in line with
data from Australia, where no effect on hospitalizations for all-
cause pneumonia were detected up to 9 years after introduction
of PCV7 into the pediatric vaccination program (14, 15) or the
Netherlands up to 3 years after pediatric PCV10 introduction
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TABLE 3 | Effect of age and other risk factors on in-hospital mortality and length of stay in patients with a pneumonia diagnosis or a pneumococcal pneumonia diagnosis.
Risk factor Multivariable analysis in-hospital mortality Multivariable analysis LOS
aOR 95% CI p aRR 95% CI p
Patients with a pneumonia diagnosis
Age ≥50y 4.73 4.12–5.05 <0.001 1.19 1.19–1.19 <0.001
Any risk factor (except for age) 2.32 2.10–2.57 <0.001 1.32 1.32–1.33 <0.001
Interaction 0.49 0.45–0.55 <0.001 0.80 0.79–0.80 <0.001
Age ≥65y 2.38 2.30–2.47 <0.001 1.16 1.16–1.17 <0.001
Any risk factor (except for age) 1.48 1.41–1.55 <0.001 1.24 1.24–1.25 <0.001
Interaction 0.76 0.72–0.80 <0.001 0.83 0.82–0.83 <0.001
Patients with a pneumococcal pneumonia diagnosis
Age ≥50y 2.84 2.22–3.63 <0.001 1.24 1.22–1.25 <0.001
Any risk factor (except for age) 1.89 1.31–2.72 <0.001 1.32 1.29–1.34 <0.001
Interaction 0.60 0.41–0.87 0.008 0.87 0.85–0.89 <0.001
Age ≥65y 2.69 2.25–3.22 <0.001 1.20 1.19–1.21 <0.001
Any risk factor (except for age) 1.69 1.36–2.09 <0.001 1.32 1.30–1.34 <0.001
Interaction 0.60 0.47–0.77 <0.001 0.83 0.82–0.84 <0.001
LOS, length of stay; aOR, adjusted odds ratio; aRR, adjusted relative risk.
(16). In contrast, Finish (17), Brazilian (18), and some US data
indicated a decline in all-cause pneumonia hospitalizations and
pneumococcal hospitalizations in at least some non-vaccinated
adult age groups (7, 19–21), but usually not in all adult age
groups whereas others did not note any declines (22, 23) as
recently summarized by Wiese et al. (24). However, the general
lack of surveillance data on pneumonia further adds value to our
analysis. In addition, our demonstration of similar time trends
regardless, whether pneumonia (or pneumococcal pneumonia)
was listed as any diagnosis or as primary diagnosis (which likely
represent the most severe cases), further strengthens the validity
of our results. Of note, our observations extend up to 10 years
after PCV7 was recommended for children in Switzerland and
4 years after it was replaced by PCV13 making a lag time
bias unlikely as the only explanation for still increasing adult
pneumonia hospitalizations.
Limitations of the study include that data were only available
for pneumonia cases which required hospitalization. This leads
to a selection bias toward more severe pneumonia episodes and
reflects the burden of severe pneumonia, but underestimates
the total vaccine-preventable burden of pneumonia. Due to the
lack of a diagnostic gold standard, pneumonia is a difficult
outcome to analyse and can be subject to reporting bias.
In addition, this analysis relies on the coding quality of the
hospitals. For some PCV13 indications there were no perfectly
matching ICD-10 codes. We included pneumonia as the main
and the additional diagnosis. Since microbiological diagnoses
are neither reliably coded, identified, or even attempted we did
not separately analyse episodes of pneumonia due to organisms
other than pneumococcus. We also included codes of bacterial
pneumonia with other pathogens than pneumococcus given the
low sensitivity of pneumococcal etiologic diagnosis (25, 26) and
the possibility of undetected coinfection with pneumococcus
(27). Our subgroup analysis of only those hospitalizations with
pneumococcal pneumonia increased the diagnostic specificity
of this vaccine-preventable disease, whereas there is certainly
considerably underreporting and therefore decreased sensitivity
with this analysis. Thus, our analyses of pneumococcal
pneumonia hospitalization incidence are likely an underestimate
of the potentially vaccine-preventable pneumococcal disease
burden, while the lack of serotype information contributes
to this uncertainty. Similarly, predictions of effects of adult
pneumococcal vaccination on pneumonia mortality cannot be
made based on our data. The presence of collinearity between the
independent variables (age and risk factors) cannot be excluded.
However, the standard errors associated with our parameter
estimates suggest that there is an adequate precision in all our
models. The putative presence of collinearity does not seem to
affect our findings. Unfortunately, the national hospitalization
database does not list age as a continuous variable but only as age
categories which does not allow to identify an age cut-off for an
increased risk of pneumonia. Nonetheless, our study examines
two important age cut-offs, which are used in many national
vaccination programs (50 and 65 years).
Important strengths are the comprehensive nationwide
coverage and the resulting large number of included pneumonia
episodes, which illustrates the magnitude of this public health
question. This database represents a unique and important
source of information as pneumonia surveillance data are
scarce. We confirmed that risk factors which had been
selected as indication for pneumococcal vaccination by experts
based on previous data or biologic plausibility were indeed
associated with risk for pneumonia hospitalization. Our results
identify age as an independent risk factor for pneumonia
hospitalization and in particular pneumococcal pneumonia
hospitalization in Switzerland. Inclusion of age in the list
of pneumococcal vaccine indications would increase eligibility
for pneumococcal vaccine. This has to be viewed in light of
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immunosenescence and potentially lower immunogenicity of
vaccines in elderly, whereas there was no lower immunogenicity
for PCV13 among older age groups in the CAPITA study
(28). Other factors to consider are pneumococcal serotype
replacement after introduction of pediatric pneumococcal
vaccination and unknown effects of future higher-valency
vaccines. Importantly, it may facilitate vaccine uptake as
annual influenza vaccine is also recommended in Switzerland
for all persons ≥65 years and could be performed during
the same office visit. Our time trends reflect the impact
of pediatric PCV introduction on adult hospitalization as
prior to 2014 only the 23-valent polysaccharide vaccine with
its limited effect on pneumococcal hospitalization (29) was
recommended for persons above age 2 years with pneumococcal
risk factors. Future trends in pneumonia hospitalization will
have to be monitored to assess the ongoing impact of pediatric
PCV implementation.
In conclusion, those conditions which are listed as indications
for pneumococcal vaccination by Swiss national vaccination
guidelines were confirmed as independent risk factors for
pneumonia hospitalizations. Pending cost-effectiveness analyses,
older age, even in the absence of additional risk factors,
should be considered to be added as an indication for
pneumococcal vaccine.
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